Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens

被引:26
作者
Hermann, S
Klein, SA
Jacobi, V
Thalhammer, A
Bialleck, H
Duchscherer, M
Wassmann, E
Hoelzer, D
Martin, H
机构
[1] Goethe Univ Frankfurt, Dept Haematol & Oncol, D-60590 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Radiol, D-6000 Frankfurt, Germany
[3] Goethe Univ Frankfurt, Inst Transfus Med, D-6000 Frankfurt, Germany
关键词
high-risk leukaemia; allogeneic bone marrow transplantation; non-myeloablative conditioning; pulmonary aspergillus; granulocyte tranfusions;
D O I
10.1046/j.1365-2141.2001.02747.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leukaemic patients with advanced disease and severe fungal infections as well as older patients with substantial co-morbidity are usually excluded from conventional allotransplantation because of increased morbidity and mortality. We approached allogeneic transplantation in four patients with a median age of 62 years (one chronic myeloid leukaemia in blast crisis, one high-risk acute myeloid leukaemia (AML) in first complete remission (CR1), one AML in 2nd relapse, one AML in CR2 with pre-existing fungal lung infections (two aspergillus, two mucor) and additional co-morbidity (diabetes n = 2, aortic aneurysm n = 1, arterial sclerosis n = 2) by combining non-myeloablative conditioning with an intensified supportive care regimen, including amphotericin B and 4-12 (median 9) prophylactic granulocyte transfusions from granulocyte colony-stimulating factor (G-CSF)-stimulated volunteer donors. G-CSF was also given to patients until neutrophil recovery All four patients recovered to a neutrophil count of 0.5 x 10(9)/l after a median of 11.5 d (range 11-13 d). Prophylactic granulocyte transfusions also reduced the need for platelet transfusions and minimized mucositis. All patients were discharged at a median of 25 d (range 18-59 d) and are alive and well after a median follow-up of > 390 d (range 336-417 d) without evidence of leukaemia. Regression of the fungal lesions was documented in three patients, with a slight progression detected by computerized tomography scan of the chest in one patient. We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF.
引用
收藏
页码:446 / 454
页数:9
相关论文
共 35 条
[1]   Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: Analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts [J].
Adkins, D ;
Spitzer, G ;
Johnston, M ;
Velasquez, W ;
Dunphy, F ;
Petruska, P .
TRANSFUSION, 1997, 37 (07) :737-748
[2]   THE EFFECTS OF DAILY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR ADMINISTRATION ON NORMAL GRANULOCYTE DONORS UNDERGOING LEUKAPHERESIS [J].
BENSINGER, WI ;
PRICE, TH ;
DALE, DC ;
APPELBAUM, FR ;
CLIFT, R ;
LILLEBY, K ;
WILLIAMS, B ;
STORB, R ;
THOMAS, ED ;
BUCKNER, CD .
BLOOD, 1993, 81 (07) :1883-1888
[3]   GRANULOCYTE TRANSFUSIONS - EFFICACY IN TREATING FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS FOLLOWING BONE-MARROW TRANSPLANTATION [J].
BHATIA, S ;
MCCULLOUGH, J ;
PERRY, EH ;
CLAY, M ;
RAMSAY, NKC ;
NEGLIA, JP .
TRANSFUSION, 1994, 34 (03) :226-232
[4]   A second unrelated bone marrow transplant: successful quantitative monitoring of mixed chimerism using a highly discriminative PCR-STR system [J].
Blau, IW ;
Basara, N ;
Serr, A ;
Seidl, C ;
Seifried, E ;
Fuchs, M ;
Bischoff, M ;
Roemer, E ;
Fauser, AA .
CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (02) :133-138
[5]   EFFECTIVE STIMULATION OF DONORS FOR GRANULOCYTE TRANSFUSIONS WITH RECOMBINANT METHIONYL GRANULOCYTE-COLONY-STIMULATING FACTOR [J].
CASPAR, CB ;
SEGER, RA ;
BURGER, J ;
GMUR, J .
BLOOD, 1993, 81 (11) :2866-2871
[6]  
Castagnola E, 1996, BONE MARROW TRANSPL, V18, P97
[7]  
Champlin Richard, 1999, Current Opinion in Oncology, V11, P87
[8]   Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect [J].
Childs, RW ;
Clave, E ;
Tisdale, J ;
Plante, M ;
Hensel, N ;
Barrett, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2044-2049
[9]  
CLARKE K, 1995, BONE MARROW TRANSPL, V16, P723
[10]   Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age [J].
Deeg, HJ ;
Shulman, HM ;
Anderson, JE ;
Bryant, EM ;
Gooley, TA ;
Slattery, JT ;
Anasetti, C ;
Fefer, A ;
Storb, R ;
Appelbaum, FR .
BLOOD, 2000, 95 (04) :1188-1194